CC
Casdin Capital Portfolio holdings
AUM
$1.1B
1-Year Return
24.98%
This Quarter Return
-15.27%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$3.55B
AUM Growth
-$460M
(-11%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
6.86%
Top 10 Holdings %
Top 10 Hldgs %
53.02%
Holding
59
New
5
Increased
5
Reduced
13
Closed
5
Top Buys
| 1 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
+$270M |
| 2 |
Guardant Health
GH
|
+$79M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$22.5M |
| 4 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
+$22.4M |
| 5 |
Seer Inc
SEER
|
+$14.8M |
Top Sells
| 1 |
Twist Bioscience
TWST
|
+$25.5M |
| 2 |
Exact Sciences
EXAS
|
+$24.9M |
| 3 |
Ginkgo Bioworks
DNA
|
+$23.9M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$22.9M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$17.6M |
Sector Composition
| 1 | Healthcare | 94.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioLife Solutions
BLFS
$1.22B
| $282M | 7.95% |
7,566,292
| – | – |
|
|
EQRX
2
DELISTED
EQRx, Inc. Common Stock
EQRX
| $270M | 7.6% |
+39,527,669
| New | +$270M |
|
3
Fate Therapeutics
FATE
$111M
| $199M | 5.61% |
3,400,000
| – | – |
|
|
NVTA
4
DELISTED
Invitae Corporation
NVTA
| $186M | 5.25% |
12,203,669
| – | – |
|
5
Alnylam Pharmaceuticals
ALNY
$61.1B
| $170M | 4.78% |
1,000,000
| – | – |
|
|
BPMC
6
DELISTED
Blueprint Medicines
BPMC
| $166M | 4.68% |
1,550,000
| – | – |
|
7
Pacific Biosciences
PACB
$351M
| $163M | 4.61% |
7,990,652
| – | – |
|
|
8
Exact Sciences
EXAS
$10.2B
| $159M | 4.48% |
2,040,000
-320,186
| -14% | -$24.9M |
|
|
SLGC
9
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $144M | 4.06% |
12,389,082
| – | – |
|
10
MaxCyte
MXCT
$155M
| $142M | 4.01% |
13,971,334
| – | – |
|
11
Codexis
CDXS
$219M
| $135M | 3.82% |
4,330,000
| – | – |
|
|
12
Sarepta Therapeutics
SRPT
$1.82B
| $122M | 3.43% |
1,350,000
+250,000
| +23% | +$22.5M |
|
13
Relay Therapeutics
RLAY
$688M
| $118M | 3.34% |
3,857,253
+188,679
| +5% | +$5.79M |
|
|
VERV
14
DELISTED
Verve Therapeutics
VERV
| $116M | 3.26% |
3,138,167
+100,000
| +3% | +$3.69M |
|
|
15
Guardant Health
GH
$6.85B
| $79M | 2.23% |
+790,000
| New | +$79M |
|
16
Agios Pharmaceuticals
AGIO
$2.14B
| $68.7M | 1.94% |
2,090,000
-75,000
| -3% | -$2.47M |
|
17
Tenaya Therapeutics
TNYA
$196M
| $68M | 1.92% |
3,586,818
| – | – |
|
18
Denali Therapeutics
DNLI
$2.07B
| $66.9M | 1.89% |
1,500,000
-200,000
| -12% | -$8.92M |
|
19
Beam Therapeutics
BEAM
$2.08B
| $65.3M | 1.84% |
818,820
| – | – |
|
20
Absci
ABSI
$381M
| $63.3M | 1.78% |
7,718,593
| – | – |
|
21
Tango Therapeutics
TNGX
$727M
| $60M | 1.69% |
5,487,910
| – | – |
|
22
Revolution Medicines
RVMD
$8.7B
| $59.7M | 1.68% |
2,370,000
-430,000
| -15% | -$10.8M |
|
23
CareDx
CDNA
$720M
| $52.5M | 1.48% |
1,153,335
-40,000
| -3% | -$1.82M |
|
|
24
Twist Bioscience
TWST
$1.53B
| $51.9M | 1.46% |
670,000
-330,000
| -33% | -$25.5M |
|
25
Century Therapeutics
IPSC
$43.3M
| $50.9M | 1.43% |
3,206,380
| – | – |
|